MedTrace Logo

A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)

NCT07547787 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 610

Last updated 2026-04-23

No results posted yet for this study

Summary

This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.

Conditions

  • Locally Advanced Unresectable or Metastatic Gastric Cancer

Sponsors & Collaborators

Principal Investigators

  • Jiafu Ji, MD · Peking University Cancer Hospital & Institute

  • Lin Shen, MD · Peking University Cancer Hospital & Institute

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-26
Primary Completion
2030-12-31
Completion
2040-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07547787 on ClinicalTrials.gov